Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Bird, Aikaterini Panopoulou, Robyn Shea, Micky Tsui, R. Saso, A. Sud, S. West, Katy Smith, John Barwood, E. Kaczmarek, Carmela Panlaqui, M. Kaiser, S. Stern, C. Pawlyn, K. Boyd (2021)
Response to first vaccination against SARS-CoV-2 in patients with multiple myelomaThe Lancet. Haematology, 8
( Gavriatopoulou M , Ntanasis‐Stathopoulos I , Korompoki E , Terpos E , Dimopoulos MA . SARS‐CoV‐2 vaccines in patients with multiple myeloma. HemaSphere. 2021;5(3):e547.33623886)
Gavriatopoulou M , Ntanasis‐Stathopoulos I , Korompoki E , Terpos E , Dimopoulos MA . SARS‐CoV‐2 vaccines in patients with multiple myeloma. HemaSphere. 2021;5(3):e547.33623886Gavriatopoulou M , Ntanasis‐Stathopoulos I , Korompoki E , Terpos E , Dimopoulos MA . SARS‐CoV‐2 vaccines in patients with multiple myeloma. HemaSphere. 2021;5(3):e547.33623886, Gavriatopoulou M , Ntanasis‐Stathopoulos I , Korompoki E , Terpos E , Dimopoulos MA . SARS‐CoV‐2 vaccines in patients with multiple myeloma. HemaSphere. 2021;5(3):e547.33623886
( Chari A , Samur MK , Martinez‐Lopez J , et al. Clinical features associated with COVID‐19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020;136(26):3033‐3040.33367546)
Chari A , Samur MK , Martinez‐Lopez J , et al. Clinical features associated with COVID‐19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020;136(26):3033‐3040.33367546Chari A , Samur MK , Martinez‐Lopez J , et al. Clinical features associated with COVID‐19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020;136(26):3033‐3040.33367546, Chari A , Samur MK , Martinez‐Lopez J , et al. Clinical features associated with COVID‐19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020;136(26):3033‐3040.33367546
( Ludwig H , Boccadoro M , Moreau P , et al. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2021;35(1):31‐44.32814840)
Ludwig H , Boccadoro M , Moreau P , et al. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2021;35(1):31‐44.32814840Ludwig H , Boccadoro M , Moreau P , et al. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2021;35(1):31‐44.32814840, Ludwig H , Boccadoro M , Moreau P , et al. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2021;35(1):31‐44.32814840
M. Gavriatopoulou, I. Ntanasis-Stathopoulos, E. Korompoki, E. Terpos, M. Dimopoulos (2021)
SARS-CoV-2 Vaccines in Patients With Multiple MyelomaHemaSphere, 5
H. Ludwig, M. Boccadoro, P. Moreau, J. San-Miguel, M. Cavo, C. Pawlyn, S. Zweegman, T. Facon, C. Driessen, R. Hájek, M. Dimopoulos, F. Gay, H. Avet-Loiseau, E. Terpos, N. Zojer, M. Mohty, M. Mateos, H. Einsele, M. Delforge, J. Caers, K. Weisel, G. Jackson, L. Garderet, M. Engelhardt, N. Donk, X. Leleu, H. Goldschmidt, M. Beksaç, I. Nijhof, N. Abildgaard, S. Bringhen, P. Sonneveld (2020)
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma NetworkLeukemia, 35
( Shah V , Ko Ko T , Zuckerman M , et al. Poor outcome and prolonged persistence of SARS‐CoV‐2 RNA in COVID‐19 patients with haematological malignancies; King's College Hospital experience. Br J Haematol. 2020;190(5):e279‐e282.32526039)
Shah V , Ko Ko T , Zuckerman M , et al. Poor outcome and prolonged persistence of SARS‐CoV‐2 RNA in COVID‐19 patients with haematological malignancies; King's College Hospital experience. Br J Haematol. 2020;190(5):e279‐e282.32526039Shah V , Ko Ko T , Zuckerman M , et al. Poor outcome and prolonged persistence of SARS‐CoV‐2 RNA in COVID‐19 patients with haematological malignancies; King's College Hospital experience. Br J Haematol. 2020;190(5):e279‐e282.32526039, Shah V , Ko Ko T , Zuckerman M , et al. Poor outcome and prolonged persistence of SARS‐CoV‐2 RNA in COVID‐19 patients with haematological malignancies; King's College Hospital experience. Br J Haematol. 2020;190(5):e279‐e282.32526039
A. Chari, M. Samur, J. Martínez-López, G. Cook, N. Biran, K. Yong, V. Hungria, M. Engelhardt, F. Gay, A. Feria, S. Oliva, R. Oostvogels, A. Gozzetti, C. Rosenbaum, Shaji Kumar, E. Stadtmauer, H. Einsele, M. Beksaç, K. Weisel, K. Anderson, M. Mateos, P. Moreau, J. San-Miguel, N. Munshi, H. Avet-Loiseau (2020)
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data setBlood, 136
V. Shah, Thinzar Ko, M. Zuckerman, Jennifer Vidler, Sobia Sharif, V. Mehra, Shreyans Gandhi, A. Kuhnl, D. Yallop, D. Avenoso, C. Rice, R. Sanderson, Anita Sarma, J. Marsh, H. Lavallade, P. Krishnamurthy, P. Patten, R. Benjamin, V. Potter, M. Ceesay, G. Mufti, S. Norton, A. Pagliuca, J. Galloway, A. Kulasekararaj (2020)
Poor outcome and prolonged persistence of SARS‐CoV‐2 RNA in COVID‐19 patients with haematological malignancies; King's College Hospital experienceBritish Journal of Haematology, 190
( Bird S , Panopoulou A , Shea RL , et al. Response to first vaccination against SARS‐CoV‐2 in patients with multiple myeloma. Lancet Haematol. 2021;8:e389‐e392.33887255)
Bird S , Panopoulou A , Shea RL , et al. Response to first vaccination against SARS‐CoV‐2 in patients with multiple myeloma. Lancet Haematol. 2021;8:e389‐e392.33887255Bird S , Panopoulou A , Shea RL , et al. Response to first vaccination against SARS‐CoV‐2 in patients with multiple myeloma. Lancet Haematol. 2021;8:e389‐e392.33887255, Bird S , Panopoulou A , Shea RL , et al. Response to first vaccination against SARS‐CoV‐2 in patients with multiple myeloma. Lancet Haematol. 2021;8:e389‐e392.33887255
(2020)
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and metaanalysis of 3377 patients
( Vijenthira A , Gong IY , Fox TA , et al. Outcomes of patients with hematologic malignancies and COVID‐19: a systematic review and meta‐analysis of 3377 patients. Blood. 2020;136(25):2881‐2892.33113551)
Vijenthira A , Gong IY , Fox TA , et al. Outcomes of patients with hematologic malignancies and COVID‐19: a systematic review and meta‐analysis of 3377 patients. Blood. 2020;136(25):2881‐2892.33113551Vijenthira A , Gong IY , Fox TA , et al. Outcomes of patients with hematologic malignancies and COVID‐19: a systematic review and meta‐analysis of 3377 patients. Blood. 2020;136(25):2881‐2892.33113551, Vijenthira A , Gong IY , Fox TA , et al. Outcomes of patients with hematologic malignancies and COVID‐19: a systematic review and meta‐analysis of 3377 patients. Blood. 2020;136(25):2881‐2892.33113551
American Journal of Hematology – Wiley
Published: Dec 1, 2021
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.